Perspective Guangxi medicine: does Shenzhen GPO price follow or not?

Recently, there are many and miscellaneous news about drug purchase in Guangxi Shenzhen GPO and Wuzhou officially signed a regional procurement alliance, and the first batch of varieties (438 varieties + 25 anticancer drugs) officially launched on February 20 From the list of the first batch of distributors released on February 16, it can be seen that, first, there are only 30 distributors in a small number, second, the gold content is not high, and Guangxi's local large-scale businesses are not among them In order to ensure timely delivery, Shenzhen GPO forwarded the notice on opening up supplementary registration work for distribution enterprises in Wuzhou on February 20, which extended the delivery time At present, the industry is more concerned about the effect of the linkage between Shenzhen GPO and Wuzhou According to roadside unconfirmed information, this linkage has caused a certain shake in Guangxi pharmaceutical market Shenzhen GPO has killed half the way to transmit the low price to Wuzhou Whether it is a pharmaceutical manufacturer or a pharmaceutical commercial company, there are objections, silences and support However, people are more concerned about the price transmission effect of Shenzhen GPO linkage In fact, the main concerns of pharmaceutical companies are focused on four aspects: first, Wuzhou in Shenzhen has won the bid, and the low price of manguan in Shenzhen Second, if Shenzhen wins the bid but Wuzhou fails to win the bid, will it bring the low-cost bid winning product specification to Wuzhou Third, how long will the coexistence of Shenzhen price and provincial price last in the future Fourth, will the upcoming provincial linkage refer to the GPO price and so on At present, relevant rumors are that if Shenzhen GPO price is selected, shenzhen price will be implemented from now on If Shenzhen GPO price is not selected, the provincial platform purchase will set a transition period for drug companies to clear inventory The most headache is that Guangxi should carry out provincial price linkage Last year's draft showed that the evaluation value of the effective bid price of drugs published and implemented by the five provinces with the lowest price in the country (the province that adopts the two envelope system to purchase drugs through public bidding) will be taken as the price linkage benchmark and the up-down linkage will be implemented The drugs that enter the price linkage range will be published on the drug purchase platform of the autonomous region The manufacturer can choose to confirm or apply for withdrawal The drugs that apply for withdrawal cannot enter the online or record sales in this purchase cycle The hospital stops purchasing! It is understood that the latest price linkage consultation draft will be released in the near future, when the price linkage will be inevitable The pharmaceutical companies that just participated in GPO in Guangzhou have actually suffered a dumb loss Fujian's price has been said to be picked Guangzhou has not yet proved why Fujian belongs to centralized procurement So, do pharmaceutical companies participating in GPO linkage in Shenzhen continue to do so? It's not the question of whether to participate or not Until now, it's a false proposition that the price that was originally agreed is not open At the beginning, I didn't say that we should link Heilongjiang in the north and Guangxi in the south, but now? Finally, with the establishment of the medical security bureau, will there be any changes in drug procurement in Guangxi? A drug purchase in Guangxi, in fact, has reflected the phenomenon of drug purchase in most areas of China, that is: fragmented, low direction is to take! In 2019, it is even more difficult for pharmaceutical companies to purchase drugs.